Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8486914 | 0.89 | MLNR (0.48) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL6846728 | 0.85 | CYP4F2 (0.72) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL14681244 | 0.85 | CYP4F2 (0.72) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL29397407 | 0.85 | CYP4F2 (0.72) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL19174157 | 0.85 | CYP4F2 (0.72) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL908570 | 0.85 | CYP4F2 (0.72) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL3969356 | 0.85 | HTR2A (0.43) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL17011671 | 0.85 | MLNR (0.45) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL3900279 | 0.85 | MLNR (0.45) | CYP4F2CYP4A11MLNRADRB2ADRB1 | |
| SCHEMBL13762731 | 0.84 | CYP4F2 (0.49) | CYP4F2CYP4A11MLNRADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1803716-B1 | A process for preparation of racemic nebivolol | ACINO PHARMA AG (CH) | 2012-07-25 | — | — | EP | disclosed |
| EP-1803716-B1 | A process for preparation of racemic nebivolol | ACINO PHARMA AG (CH) | 2012-07-25 | — | — | EP | disclosed |
| US-7560575-B2 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2009-07-14 | — | — | US | disclosed |
| US-7560575-B2 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2009-07-14 | — | — | US | disclosed |
| US-7560575-B2 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2009-07-14 | — | — | US | disclosed |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (CH) | 2009-02-19 | — | — | US | disclosed |
| WO-2008010022-A2 | A PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008010022-A2 | A PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1803716-A1 | A process for preparation of racemic nebivolol | Cimex Pharma AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| EP-1803716-A1 | A process for preparation of racemic nebivolol | Cimex Pharma AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| EP-1803715-A1 | A process for preparation of racemic nebivolol | Cimex Pharma AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| EP-1803715-A1 | A process for preparation of racemic nebivolol | Cimex Pharma AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2007-06-28 | — | — | US | disclosed |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2007-06-28 | — | — | US | disclosed |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | ADRB1, ADRB2, ADRA2B | CYP4F2 258/4885CYP4A11 35/4885MLNR 452/4885 |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ADRB1, ADRB2, ADRA2B | CYP4F2 258/4885CYP4A11 35/4885MLNR 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.